Melanotan I vs Tripeptide-10 Citrulline
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Afamelanotide, Scenesse
Melanotan I is the research name for afamelanotide (code CUV1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. Sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), one of a few approved melanocortin drugs alongside bremelanotide (Vyleesi) and setmelanotide (Imcivree). The approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. The injectable 'Melanotan I' sold online is not approved for anything.
Also: Decorinyl, Decorin-like tetrapeptide
Tripeptide-10 citrulline, sold as Decorinyl, is a small synthetic peptide (four residues, despite the name) designed by the Spanish ingredient maker Lipotec to mimic decorin, a protein that keeps collagen fibers neat and evenly sized. The pitch is better collagen, not more collagen. It is a cosmetic ingredient, not an FDA-approved drug, and almost all of the evidence comes from the company that makes it.
Key Comparison Insights
- Melanotan I is FDA approved, while Tripeptide-10 Citrulline remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to Tripeptide-10 Citrulline (Limited Research).
Detailed Comparison
| Attribute | Melanotan I | Tripeptide-10 Citrulline |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent. | Decorin sits on collagen fibrils and controls how thick they grow and how tightly they pack. With age, decorin activity drops, and collagen fibers become uneven and disorganized, which is part of why older skin loses suppleness. Lipotec researchers took the two short sequences decorin uses to grab collagen, built a library of tetrapeptides around them, and screened them in a test-tube collagen assembly assay. The winner, tripeptide-10 citrulline, made fibrils thinner and more uniform in that assay. The idea is that a well-organized collagen network is more cohesive and supple. Whether a topical cream delivers enough peptide to the dermis to do this in real skin has not been independently shown. |
| Common Dosing | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance | Around 0.01% peptide in a finished product Once or twice daily |
| Administration | Subcutaneous implant (not injection) | Topical (serums, creams) |
| Typical Duration | Long-term / as needed before sun season | Studies ran 2 months (60 days); ongoing use for maintained effects |
| Best Time to Take | Before the sunny season (approved implant); evening for unapproved injectables | Morning and/or evening skincare routine |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU (74) and US (94) who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (median 69.4 vs 40.8 hours in the US trial; 6.0 vs 0.8 hours in the EU trial, where phototoxic reactions also dropped from 146 to 77), and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. Clinuvel is also running a phase 3 vitiligo trial (CUV105), with topline results guided for December 2026. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane. | The founding paper is Puig, Garcia Anton and Mangues (Lipotec) in the Journal of Cosmetic Science, 2008, which describes the in vitro fibrillogenesis screen. Trade press reporting of the same company work described a 0.01 percent formula applied for two months that made collagen fibers more uniform in a handful of volunteers, and a placebo comparison (22 women on peptide, 21 on placebo) reporting a 54 percent rise in suppleness. Those numbers come from the manufacturer and are not easy to check against full published data. The one independent-looking human trial is Raikou and colleagues, Journal of Cosmetic Dermatology 2017: 24 volunteers split into four groups (combination with acetyl hexapeptide-3, each peptide alone, or neither) for 60 days, with some statistically significant differences in wrinkle microtopography and water loss. Six people per group is very small, and the authors themselves could not explain any synergy. Fair summary: a clever design with real in vitro logic, and thin human data. |
Frequently Asked Questions: Melanotan I vs Tripeptide-10 Citrulline
What is the difference between Melanotan I and Tripeptide-10 Citrulline?
Melanotan I is a skin & hair peptide that melanotan i is the research name for afamelanotide (code cuv1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-msh), also written as [nle4, d-phe7]-alpha-msh or ndp-msh. sold as scenesse, it was approved by the ema in 2014 and the fda in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (epp), one of a few approved melanocortin drugs alongside bremelanotide (vyleesi) and setmelanotide (imcivree). the approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. the injectable 'melanotan i' sold online is not approved for anything. Tripeptide-10 Citrulline is a skin & hair peptide that tripeptide-10 citrulline, sold as decorinyl, is a small synthetic peptide (four residues, despite the name) designed by the spanish ingredient maker lipotec to mimic decorin, a protein that keeps collagen fibers neat and evenly sized. the pitch is better collagen, not more collagen. it is a cosmetic ingredient, not an fda-approved drug, and almost all of the evidence comes from the company that makes it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Melanotan I or Tripeptide-10 Citrulline?
Neither is universally "better" - the choice depends on your specific goals. Melanotan I is typically used for skin & hair purposes, while Tripeptide-10 Citrulline is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Melanotan I and Tripeptide-10 Citrulline be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Melanotan I and Tripeptide-10 Citrulline together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.